The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
23-Apr-18
$NA
Target:
Grupo Proenfar
Acquiror:
Weener Plastics
Advised Grupo Proenfar, a Colombia-based plastics packaging solutions provider, and its shareholders on its sale to Weener Plastics
27-Mar-18
$13.0 billion
Target:
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
Acquiror:
GlaxoSmithKline plc
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
26-Feb-18
$224 million
Target:
Crem International
Acquiror:
Welbilt
Advised Welbilt, a leading global provider of commercial foodservice equipment on its acquisition of Crem International, a leading manufacturer of professional coffee machines
19-Feb-18
$531 million
Target:
Faster S.p.A.
Acquiror:
Sun Hydraulics Corporation
Advised Capvis Equity Partners on the sale of its portfolio company Faster Group, a producer of quick-release hydraulic couplings, to Sun Hydraulics
18-Dec-17
$6.0 billion
Target:
CB&I
Acquiror:
McDermott International, Inc.
Advised McDermott International, Inc., a leading provider of integrated engineering, procurement, construction, installation and module fabrication services for upstream field developments worldwide, on its combination with CB&I, a leading provider of technology and infrastructure for the energy industry
14-Dec-17
$NA
Target:
36.5% stake in DNV GL Group AS
Acquiror:
Det Norske Veritas Holding AS
Advised Det Norske Veritas Holding AS (“DNV”) on its acquisition of the 36.5% stake in DNV GL Group AS it did not already own from Mayfair Vermögensverwaltungs SE, whereby DNV is becoming the sole shareholder and regaining full control of DNV GL
30-Nov-17
$NA
Target:
MorphoSys AG
Acquiror:
I-Mab
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
20-Nov-17
$412 million
Target:
Godfrey Hirst
Acquiror:
Mohawk Industries
Advised Godfrey Hirst, the leading manufacturer, distributor and marketer of carpet and hard flooring in Australia and New Zealand, on its sale to Mohawk Industries, the NYSE-listed global flooring company
05-Nov-17
$NA
Target:
Jaybro
Acquiror:
CHAMP Private Equity
Advised Jaybro, a leading supplier of consumables to infrastructure contractors, on its sale to CHAMP Private Equity
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
01-Sep-17
$NA
Target:
B-G Mechanical Contractors, Inc., B-G Mechanical Services, Inc., Elmsford Sheet Metal Works, Inc., Fred Williams, Inc., H.T. Lyons, Inc. and TryState Mechanical, Inc.
Acquiror:
ENGIE North America
Advised Talen Energy, one of the largest independent energy and power producers in the United States, on the sale of six subsidiaries, within its Mechanical Services business, to Engie North America
24-Aug-17
$NA
Target:
Morris Corporation
Acquiror:
Sodexo SA
Advised Morris Corporation, a leading independent player in Australia’s remote facilities management sector, on its sale to Sodexo SA, a France-based leading global facilities services company
23-Aug-17
$NA
Target:
Thermamax
Acquiror:
Capvis Equity Partners
Advised the shareholders of Thermamax, a leading family-owned manufacturer of highly engineered high temperature insulation solutions on the sale of the Company
14-Jul-17
$775 million
Target:
Programmed Maintenance Services Limited
Acquiror:
PERSOL HOLDINGS CO LTD.
Advised PERSOL HOLDINGS, one of Japan’s largest HR service companies, on its acquisition of ASX-listed Programmed Maintenance Services, a leading Australian and New Zealand based provider of staffing and maintenance services
03-Apr-17
$205 million
Target:
Inenco Group Pty Ltd
Acquiror:
Genuine Parts Company
Advised Inenco Group Pty Ltd, one of Australasia’s leading industrial distributors, on the partial sale to Genuine Parts Company, a global distributor of automotive and industrial products
12-Dec-16
$NA
Target:
Western Sydney Airport
Advised the Commonwealth Government of Australia as represented by the Department of Infrastructure and Regional Development in relation to the Western Sydney Airport (Peer Review and other strategic advisory services)
05-Dec-16
$87 million
Target:
The Franklin Printing Group Pty Ltd (“Franklin Web”) and Taverners No.13 Pty Ltd (“AIW Printing”)
Acquiror:
IVE Group Limited
Advised ASX-listed IVE Group, a leading marketing and print communications provider in Australia, on the simultaneous acquisitions of Franklin Web and AIW Printing, specialist catalogue producers, and its equity capital raising via a placement and a rights issue
24-Nov-16
$NA
Target:
Portfolio of 119 marketed and development pipeline products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Rivopharm SA
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 119 marketed and development pipeline products to Rivopharm SA
23-Nov-16
$NA
Target:
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
Acquiror:
Arrow Generiques SAS
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
14-Nov-16
$346 million
Target:
Etrion Corporation's Italian solar photovoltaic platform
Acquiror:
Ultor S.p.A.
Advised Etrion Corporation, a solar independent power producer and developer, on the sale of its 60MW Italian solar photovoltaic platform to Ultor S.p.A. (a joint venture owned equally by Enel Green Power S.p.A. and F2i Fondi Italiani per le infrastrutture) for an Enterprise Value of €323mm
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
18-Aug-16
$3.2 billion
Target:
Valves & Controls Business of Pentair
Acquiror:
Emerson
Advised Emerson, a diversified global technology and industrial company, on the acquisition of the Valves & Controls business of Pentair
09-Aug-16
$NA
Target:
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
28-Jun-16
$652 million
Target:
US rights to 37 approved and 5 pipeline generic products
Acquiror:
Mayne Pharma Group Limited
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products